by jtcir-auto | Aug 3, 2022 | Press Releases
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS)...
by jtcir-auto | Aug 3, 2022 | Press Releases
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS)...
by jtcir-auto | Jul 18, 2022 | Press Releases
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...
by jtcir-auto | Jul 18, 2022 | Press Releases
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...
by jtcir-auto | Jul 15, 2022 | Press Releases
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...